Puma Biotechnology | PBYI - Trade Creditors


Puma Biotechnology reported $6.39M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amgen USD 20.89B 1.25B Dec/2025
Biogen USD 432M 18.9M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
Esperion Therapeutics USD 77.51M 2.81M Sep/2025
Exelixis USD 29.62M 4.27M Dec/2025
Gilead Sciences USD 808M 226M Sep/2025
Glaxosmithkline GBP 21.07B 7.42B Sep/2025
Incyte USD 1.63B 1.46B Dec/2025
MacroGenics USD 5.94M 1.28M Sep/2025
Moderna USD 317M 50M Dec/2025
Novartis USD 4.56B 49M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sarepta Therapeutics USD 280.84M 186.83M Dec/2025
Takeda JPY 467.59B 28.61B Dec/2025
TG Therapeutics USD 61.64M 72.38M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025